Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gema Mateo

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2008
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapyGema Mateo, M Angeles Montalbán, Maria-Belén Vidriales, et al.
Blood|September 17, 2009
The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patientsBruno Paiva, Maria-Belén Vidriales, Gema Mateo, et al.
Blood|August 2, 2008
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantationBruno Paiva, Maria-Belén Vidriales, Jorge Cerveró, et al.
Haematologica|February 13, 2008
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disordersAndy C Rawstron, Alberto Orfao, Meral Beksac, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2008
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapyGema Mateo, M Angeles Montalbán, Maria-Belén Vidriales, et al.
Blood|September 17, 2009
The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patientsBruno Paiva, Maria-Belén Vidriales, Gema Mateo, et al.
Blood|August 2, 2008
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantationBruno Paiva, Maria-Belén Vidriales, Jorge Cerveró, et al.
Haematologica|February 13, 2008
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disordersAndy C Rawstron, Alberto Orfao, Meral Beksac, et al.
Pageof 3